🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Eidos Therapeutics Inc (EIDX)

NASDAQ
Currency in USD
Disclaimer
122.21
0.00(0.00%)
Closed
Trading near 52-week High
Fair Value
Day's Range
116.83128.49
52 wk Range
116.83128.49
Prev. Close
122.21
Open
127.57
Day's Range
116.83-128.49
52 wk Range
116.83-128.49
Volume
0
Average Volume (3m)
-
1-Year Change
0%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
EIDX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Currently not supported.
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Eidos Therapeutics Inc Company Profile

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is based in Palo Alto, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Industry
-
Sector
-
Employees
70

Compare EIDX to Peers and Sector

Metrics to compare
EIDX
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x0.0x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x0.0x
Price / LTM Sales
0.0x0.0x0.0x
Upside (Analyst Target)
0.0%0.0%0.0%
Fair Value Upside
Unlock0.0%0.0%Unlock
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.